ClinicalTrials.gg
CompletedNCT03664544MCI-186-E05 HPUpdated Jul 15, 2026Results posted

PK Study in Subjects With Severe Hepatic Impairment

A Phase 1 interventional study of MCI-186 in Severe Hepatic Impairment and Healthy, sponsored by Shionogi. Completed at 3 sites in 3 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Shionogi · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is an open-label, single-dose study in male and female subjects with severe hepatic impairment and in male and female subjects with normal hepatic function.

02

Conditions studied

  • Severe Hepatic Impairment
  • Healthy

Keywords

  • Severe Hepatic Impairment
  • Healthy
03

In context

Lead sponsor

Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.

Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All subjects

  • 1. Able to provide written to participate in this study after reading the participant information sheet and Informed Consent Form (ICF), and after having the opportunity to discuss the study with the Investigator or designee.
  • 2. Male or female subjects age 18 to 75 years (inclusive) at signature of the ICF.
  • 3. In the Investigator's opinion, subject is able to understand the nature of the study and any risks involved in participation, and willing to cooperate and comply with the Protocol restrictions and requirements.
  • 4. A body weight of ≥50 kg and a (Quetelet index) ranging from 18 to 37 kg/m2 (inclusive) at Screening and Day -1.
  • 5. Female subjects who are:

    1. for at least 1 year, confirmed by follicle-stimulating hormone assessment (>40 mIU/mL), or
    2. surgically sterilised (hysterectomy, bilateral oophorectomy or salpingectomy), or
    3. congenital sterility. Female subjects of must practice effective (see Protocol body) from the Screening Visit or at least 2 weeks before IMP administration, until 30 days after IMP dosing. Male subject must practice effective contraception from the time of IMP dosing until 90 days after IMP dosing. Adhering to strict abstinence is considered an accepted contraceptive method.

Hepatic impaired subjects (in addition)

  • 6. Diagnosis of cirrhosis due to parenchymal liver disease, which is documented in the medical history and physical examination and confirmed by at least one of the following: hepatic ultrasound, computed axial tomography scan, magnetic resonance imaging and/or liver . A classification score of 10 to 14 obtained during the Screening period (i.e., within 21 days of IMP administration).
  • 7. Chronic (>6 months) and stable hepatic impairment defined as no change in disease status at least 14 days before Screening.
  • 8. Acceptable clinical conditions in the opinion of the Investigator on the basis of a physical examination, medical history, 12-lead (ECG), vital signs and clinical laboratory tests (biochemistry, haematology, coagulation and urinalysis) at Screening, Day -1 and pre-dose on Day 1. Subjects with stable mild chronic concurrent diseases, such as degenerative joint disease, controlled diabetes, hypertension or hyperlipidaemia, etc. may be included.

Healthy subjects (in addition)

  • 9. Subjects with normal hepatic function confirmed with tests within the normal reference range or results with minor deviations which are not considered by the Investigator to be clinically significant.
  • 10. Good health and free from clinically significant illness or disease in the opinion of the Investigator on the basis of a physical examination, medical history, ECG, vital signs and clinical laboratory tests (biochemistry, haematology, coagulation and urinalysis) at Screening, Day -1 and pre-dose on Day 1.

Exclusion criteria

Exclusion Criteria:

All subjects

  • 1. Presence or history of severe allergy to food, or any medical product or relevant that is of clinical significance.
  • 2. Subjects who have previously been administered MCI-186.
  • 3. As a result of the medical screening process, the Investigator considers the subject not suitable for the study.
  • 4. 12-lead abnormalities, including but not limited to, interval using Fridericia's formula (QTcF) of >450 ms (male subjects) or >470 ms (female subjects) at Screening, Day -1 or before dosing.
  • 5. Any other history or condition (surgical or medical) of disease which will increase the risk to the subject, will affect the PK of the study drug, or will otherwise influence the assessments to be made in this study, in the opinion of the Investigator. Subjects who have undergone cholecystectomy may be included.
  • 6. History of drug abuse or tested positive for alcohol or drugs of abuse at Screening and Day -1, excluding drugs which may cause a positive drug or abuse test if medically indicated or prescribed.
  • 7. Subjects who regularly, or on average, drink more than 35 units of alcohol per week (one unit is equivalent to 300 mL of beer, 25 mL of spirits or 150 mL of wine).
  • 8. Presence of active infection requiring antibiotics.
  • 9. Positive test for antigen/antibody at Screening.
  • 10. Donation of one or more units of blood (450 mL) within 3 months prior to Screening, or plasma in the 7 days prior to Screening, or in the 6 weeks prior to Screening, or the intention to donate blood within 3 months after the last Follow-up assessment.
  • 11. Participation in another study within the last month (if single dose), or at least 4 months (if multiple dose), or within 10 times the half-life of the respective drug (whichever is longer) before Screening. For biologics, the minimum period is at least 6 months before Screening, the period of the pharmacodynamic effect, or 10 times the half life of the respective drug, whichever is longer.
  • 12. Subject is currently taking non-permitted concomitant medication. The subjects with normal hepatic function are restricted from use of any concomitant medications (including paracetamol) unless discussed and agreed with the Sponsor. In subjects with hepatic impairment, the use of prescribed medications is permitted for hepatic or concomitant disease as described in the Protocol body.
  • 13. Not willing to abstain from consumption of coffee, tea, cola, energy drinks or chocolates from admission to the unit (Day -1) to discharge from the unit (Day 3).
  • 14. Uncontrolled, or untreated hypertension defined as a mean of three repeated measurements of systolic blood pressure >180 mmHg and/or diastolic blood pressure >100 mmHg.
  • 15. Subjects have estimated \<60 mL/min/1.73 m2 as determined by Modification of Diet in Renal Disease formula.
  • 16. Any condition associated with dehydration.
  • 17. Female subjects:

    1. who have a positive pregnancy test at Screening or on Day -1.
    2. who are pregnant, lactating or planning to become pregnant during the study.

Hepatic impaired subjects (in addition)

  • 18. Subjects with severe ascites or pleural effusion which will, in the opinion of the Investigator, adversely affect the subject's ability to participate in the study.
  • 19. Subjects with severe encephalopathy (Grade III or IV).
  • 20. Subjects with sclerosing cholangitis.
  • 21. Serum albumin \<2.0 g/dL.
  • 22. \<10 g/dL.
  • 23. Start of any new medication or any changes to a current dosage within 14 days before IMP administration.

Healthy subjects (in addition)

  • 24. History or presence of any parenchymal hepatic disease.
  • 25. Positive test for surface antigen or virus antibody.
  • 26. History of or active suicidal ideation, or suicide attempt as evidenced by positive response to either Question 4 (active suicidal ideation with some intent to act) or Question 5 (active suicidal ideation with specific plan and intent) on the Columbia-Suicide Severity Rating Scale (C-SSRS; Screening Version).
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Subjects with severe hepatic impairment

    HP PK MCI-186

    Drug: MCI-186

  • Experimental
    Subjects with normal hepatic function

    NHV PK MCI-186

    Drug: MCI-186

Interventions

  • 30 mg MCI-186 will be administered intravenously over 60 minutes.

    Also known as: Edaravone, Radicava, Radicut

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic Parameters of MCI-186: Peak Drug Concentration (Cmax)

    Unchanged MCI-186

    Time frame: Day 1 to 3 (Pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h)

  2. Pharmacokinetic Parameters of MCI-186: Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last)

    Unchanged MCI-186

    Time frame: Day 1 to 3 (Pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h)

  3. Pharmacokinetic Parameters of MCI-186: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-∞)

    Unchanged MCI-186

    Time frame: Day 1 to 3 (Pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h)

Secondary outcomes

  1. Incidence of Adverse Events (AEs) and Serious Adverse Events

    Number of adverse events

    Time frame: Day -1 to Day 7

  2. Pharmacokinetic Parameters of MCI-186: Half-life (t½)

    Unchanged MCI-186

    Time frame: Day 1 to 3 (Pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h)

  3. Pharmacokinetic Parameters of MCI-186: Time to Reach Peak Concentration (Tmax)

    Unchanged MCI-186

    Time frame: Day 1 to 3 (Pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h)

  4. Pharmacokinetic Parameters of MCI-186: Terminal Elimination Rate Constant (λZ)

    Unchanged MCI-186

    Time frame: Day 1 to 3 (Pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h)

  5. Pharmacokinetic Parameters of MCI-186: Total Clearance (CL)

    Unchanged MCI-186

    Time frame: Day 1 to 3 (Pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h)

  6. Pharmacokinetic Parameters of MCI-186: Volume of Distribution at Steady State (Vss)

    Unchanged MCI-186

    Time frame: Day 1 to 3 (Pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h)

  7. Pharmacokinetic Parameters of MCI-186: Volume of Distribution During the Terminal Phase (VZ)

    Unchanged MCI-186

    Time frame: Day 1 to 3 (Pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h)

  8. Pharmacokinetic Parameters of MCI-186: Mean Residence Time (MRT)

    Unchanged MCI-186

    Time frame: Day 1 to 3 (Pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h)

  9. Pharmacokinetic Parameters of MCI-186: Unbound Area Under the Concentration-time Curve From Time Zero to Infinity (AUCu0-∞)

    Unchanged MCI-186

    Time frame: Day 1 to 3 (Pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h)

  10. Pharmacokinetic Parameters of MCI-186: Unbound Total Clearance (Clu)

    Unchanged MCI-186

    Time frame: Day 1 to 3 (Pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h)

07

Results

Posted Apr 7, 2020

Participant flow

Participant flow — Overall Study
MilestoneHP PK MCI-186NHV PK MCI-186
Started66
Completed66
Not completed00

Outcome measures

PrimaryPharmacokinetic Parameters of MCI-186: Peak Drug Concentration (Cmax)

Unchanged MCI-186

Time frame:
Day 1 to 3 (Pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h)
Reported as:
Mean · ng/mL
Pharmacokinetic Parameters of MCI-186: Peak Drug Concentration (Cmax)
ng/mLHP PK MCI-186NHV PK MCI-186
Pharmacokinetic Parameters of MCI-186: Peak Drug Concentration (Cmax)347.6 ± 146.8280.3 ± 101.0
PrimaryPharmacokinetic Parameters of MCI-186: Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last)

Unchanged MCI-186

Time frame:
Day 1 to 3 (Pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h)
Reported as:
Mean · h*ng/mL
Pharmacokinetic Parameters of MCI-186: Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last)
h*ng/mLHP PK MCI-186NHV PK MCI-186
Pharmacokinetic Parameters of MCI-186: Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last)473.90 ± 163.28394.65 ± 160.01
PrimaryPharmacokinetic Parameters of MCI-186: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-∞)

Unchanged MCI-186

Time frame:
Day 1 to 3 (Pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h)
Reported as:
Mean · h*ng/mL
Pharmacokinetic Parameters of MCI-186: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-∞)
h*ng/mLHP PK MCI-186NHV PK MCI-186
Pharmacokinetic Parameters of MCI-186: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-∞)496.98 ± 183.81416.34 ± 164.96
SecondaryIncidence of Adverse Events (AEs) and Serious Adverse Events

Number of adverse events

Time frame:
Day -1 to Day 7
Reported as:
Number · Events
Incidence of Adverse Events (AEs) and Serious Adverse Events
EventsHP PK MCI-186NHV PK MCI-186
Adverse events01
Serious adverse events00
Treatment emergent adverse events01
Adverse Drug reaction01
TEAE leading to discontinuation of study drug00
SecondaryPharmacokinetic Parameters of MCI-186: Half-life (t½)

Unchanged MCI-186

Time frame:
Day 1 to 3 (Pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h)
Reported as:
Mean · h
Pharmacokinetic Parameters of MCI-186: Half-life (t½)
hHP PK MCI-186NHV PK MCI-186
Pharmacokinetic Parameters of MCI-186: Half-life (t½)3.88 ± 1.129.51 ± 6.62
SecondaryPharmacokinetic Parameters of MCI-186: Time to Reach Peak Concentration (Tmax)

Unchanged MCI-186

Time frame:
Day 1 to 3 (Pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h)
Reported as:
Median · h
Pharmacokinetic Parameters of MCI-186: Time to Reach Peak Concentration (Tmax)
hHP PK MCI-186NHV PK MCI-186
Pharmacokinetic Parameters of MCI-186: Time to Reach Peak Concentration (Tmax)1.02 (0.25 to 1.05)1.02 (1.00 to 1.03)
SecondaryPharmacokinetic Parameters of MCI-186: Terminal Elimination Rate Constant (λZ)

Unchanged MCI-186

Time frame:
Day 1 to 3 (Pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h)
Reported as:
Mean · /h
Pharmacokinetic Parameters of MCI-186: Terminal Elimination Rate Constant (λZ)
/hHP PK MCI-186NHV PK MCI-186
Pharmacokinetic Parameters of MCI-186: Terminal Elimination Rate Constant (λZ)0.19 ± 0.060.15 ± 0.14
SecondaryPharmacokinetic Parameters of MCI-186: Total Clearance (CL)

Unchanged MCI-186

Time frame:
Day 1 to 3 (Pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h)
Reported as:
Mean · L/h
Pharmacokinetic Parameters of MCI-186: Total Clearance (CL)
L/hHP PK MCI-186NHV PK MCI-186
Pharmacokinetic Parameters of MCI-186: Total Clearance (CL)66.82 ± 21.4978.72 ± 20.51
SecondaryPharmacokinetic Parameters of MCI-186: Volume of Distribution at Steady State (Vss)

Unchanged MCI-186

Time frame:
Day 1 to 3 (Pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h)
Reported as:
Mean · L
Pharmacokinetic Parameters of MCI-186: Volume of Distribution at Steady State (Vss)
LHP PK MCI-186NHV PK MCI-186
Pharmacokinetic Parameters of MCI-186: Volume of Distribution at Steady State (Vss)133.86 ± 71.05449.79 ± 438.26
SecondaryPharmacokinetic Parameters of MCI-186: Volume of Distribution During the Terminal Phase (VZ)

Unchanged MCI-186

Time frame:
Day 1 to 3 (Pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h)
Reported as:
Mean · L
Pharmacokinetic Parameters of MCI-186: Volume of Distribution During the Terminal Phase (VZ)
LHP PK MCI-186NHV PK MCI-186
Pharmacokinetic Parameters of MCI-186: Volume of Distribution During the Terminal Phase (VZ)359.85 ± 130.061064.88 ± 888.10
SecondaryPharmacokinetic Parameters of MCI-186: Mean Residence Time (MRT)

Unchanged MCI-186

Time frame:
Day 1 to 3 (Pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h)
Reported as:
Mean · h
Pharmacokinetic Parameters of MCI-186: Mean Residence Time (MRT)
hHP PK MCI-186NHV PK MCI-186
Pharmacokinetic Parameters of MCI-186: Mean Residence Time (MRT)2.27 ± 1.875.51 ± 4.60
SecondaryPharmacokinetic Parameters of MCI-186: Unbound Area Under the Concentration-time Curve From Time Zero to Infinity (AUCu0-∞)

Unchanged MCI-186

Time frame:
Day 1 to 3 (Pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h)
Reported as:
Mean · h*ng/mL
Pharmacokinetic Parameters of MCI-186: Unbound Area Under the Concentration-time Curve From Time Zero to Infinity (AUCu0-∞)
h*ng/mLHP PK MCI-186NHV PK MCI-186
Pharmacokinetic Parameters of MCI-186: Unbound Area Under the Concentration-time Curve From Time Zero to Infinity (AUCu0-∞)65.41 ± 28.7145.33 ± 13.97
SecondaryPharmacokinetic Parameters of MCI-186: Unbound Total Clearance (Clu)

Unchanged MCI-186

Time frame:
Day 1 to 3 (Pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h)
Reported as:
Mean · L/h
Pharmacokinetic Parameters of MCI-186: Unbound Total Clearance (Clu)
L/hHP PK MCI-186NHV PK MCI-186
Pharmacokinetic Parameters of MCI-186: Unbound Total Clearance (Clu)529.83 ± 200.93702.10 ± 159.63

Adverse events

Collected over Day -1 to Day 7. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HP PK MCI-1860/6 (0%)0/6 (0%)0/6 (0%)
NHV PK MCI-1860/6 (0%)0/6 (0%)1/6 (16.7%)
Most frequent other events
Most frequent other events
EventHP PK MCI-186NHV PK MCI-186
Sinus BradycardiaCardiac disorders0/61/6

Baseline characteristics

Safety Analysis Set

Age, Categorical
Age, Categorical(Participants)HP PK MCI-186NHV PK MCI-186Total
<=18 years000
Between 18 and 65 years459
>=65 years213
Age, Continuous
Age, Continuous(years)HP PK MCI-186NHV PK MCI-186Total
Mean62.2 ± 7.953.0 ± 8.057.6 ± 9.0
Sex: Female, Male
Sex: Female, Male(Participants)HP PK MCI-186NHV PK MCI-186Total
Female112
Male5510
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)HP PK MCI-186NHV PK MCI-186Total
Hispanic or Latino000
Not Hispanic or Latino6612
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)HP PK MCI-186NHV PK MCI-186Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White6612
More than one race000
Unknown or Not Reported000
08

Study locations

3 sites
  • Investigational Centre
    Prague, Czechia
  • Investigational Centre
    Miskolc, Hungary
  • Investigational Centre
    Bratislava, Slovakia
09

References and documents

Publications

  • Nakamaru Y, Kakubari M, Yoshida K, Akimoto M, Todorovic V, Greis T, Kondo K. Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning. Clin Ther. 2020 Aug;42(8):1467-1482.e4. doi: 10.1016/j.clinthera.2020.06.016. Epub 2020 Aug 14. PubMed 32800532 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2018 to primary completion in Mar 2019, 4 months.

Results were first posted in Apr 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2018
First posted
Sep 10, 2018
StartActual
Nov 6, 2018
Primary completionActual
Mar 25, 2019
CompletionActual
Mar 25, 2019
Results first posted
Apr 7, 2020
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03664544
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Sep 10, 2018
Start date
Nov 6, 2018
Primary completion
Mar 25, 2019
Completion
Mar 25, 2019
Results posted
Apr 7, 2020
Last update
Jul 15, 2026

Study contacts

Shionogi Clinical Trials Administrator Clinical Support Help Line
study director · Shionogi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Edaravone

Start the discussion